Cargando…
Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
INTRODUCTION AND OBJECTIVE: Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is...
Autores principales: | Klein, Kevin, Scholl, Joep H. G., Vermeer, Niels S., Broekmans, André W., Van Puijenbroek, Eugène P., De Bruin, Marie L., Stolk, Pieter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735237/ https://www.ncbi.nlm.nih.gov/pubmed/26719190 http://dx.doi.org/10.1007/s40264-015-0383-8 |
Ejemplares similares
-
Challenges and Opportunities for the Traceability of (Biological) Medicinal Products
por: Klein, Kevin, et al.
Publicado: (2018) -
Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers
por: Klein, Kevin, et al.
Publicado: (2015) -
A prediction model‐based algorithm for computer‐assisted database screening of adverse drug reactions in the Netherlands
por: Scholl, Joep H.G., et al.
Publicado: (2017) -
Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands
por: Glerum, Pieter J., et al.
Publicado: (2020) -
Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection
por: Pacurariu, Alexandra C., et al.
Publicado: (2015)